Medidata Joins With GlaxoSmithKline On Mobile Health Initiative

(RTTNews) - Medidata Solutions Inc. (MDSO), a provider of cloud-based solutions for clinical research in life sciences, Monday announced the completion of a method development project conducted in partnership with GlaxoSmithKline Plc (GSK, GSK.L) to evaluate the impact of unifying mobile health or mHealth devices with cloud-based technologies in a clinical trial setting.

The company noted that the joint initiative assessed the capabilities of mHealth tools. It also evaluated how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs.

The collaborative project was took place at GSK's Human Performance Lab. It demonstrated that mHealth technologies have the power to comprehensively collect large volumes of objective data that is reliable, secure and analysis-ready, and provides real-time, continuous insight into the well being of patients.

All of the data collected was audited and is compliant with FDA regulations. Additionally, the effort indicated that mobile devices can support the long-term goal of lessening the burden on patients participating in studies by streamlining routine procedures, eliminating unnecessary ones and reducing visits to clinical trial sites.

Medidata said its data science team is working with GSK to leverage the data from the project and turn it into actionable insight that can be used to conduct faster and more patient-centric clinical research.

In addition, Medidata intends to use the technology infrastructure developed for this initiative as a model to enable new Phase I-IV mHealth clinical trials, which the company will be supporting for clients over the coming months.

Medidata shares closed Friday's trading at $41.22, down 2.81 percent.

GlaxoSmithKline are currently trading at 1,459.62 pence in London, down 0.13 percent.